{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:55:31Z","timestamp":1757703331154},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T00:00:00Z","timestamp":1389139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>The purpose of this study was to investigate the impact of risk communication about bisphosphonate (BP)\u2010related osteonecrosis of the jaw (ONJ) on the number of reported cases to the Drug Adverse Reactions Reporting System and on the incidence proportion of ONJ in a hospital\u2010based cohort study in Japan.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We conducted a survey of the safety information on BP\u2010related ONJ available from regulatory authorities, pharmaceutical manufacturers and academic associations. We also performed a trend analysis of a dataset from the Drug Adverse Reactions Reporting System and a sub\u2010analysis, using previously constructed data from a retrospective cohort study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Risk communication from pharmaceutical manufacturers and academic associations began within 1 year after revisions were made to the package inserts, in October 2006. Twenty times more cases of ONJ have been reported to regulatory authority since 2007, compared with the period before 2007. In our cohort, the incidence proportion of ONJ during and after 2009 was four times greater than before 2009. During this period, BPs were frequently prescribed, whereas there was no increase in the use of alternative agents, such as selective estrogen receptor modulators.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ONJ was increasingly diagnosed after risk communication efforts, but the impact of the communications was not clear. Safety notifications were diligently disseminated after the package insert was revised. However, there was no surveillance for ONJ before the revision. \u00a9 2014 The Authors. <jats:italic>Pharmacoepidemiology and Drug Safety<\/jats:italic> published by John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.3562","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T05:54:54Z","timestamp":1389160494000},"page":"398-405","source":"Crossref","is-referenced-by-count":10,"title":["The increase in prescriptions of bisphosphonates and the incidence proportion of osteonecrosis of the jaw after risk communication activities in Japan: a hospital\u2010based cohort study"],"prefix":"10.1002","volume":"23","author":[{"given":"Eriko","family":"Sumi","sequence":"first","affiliation":[{"name":"Department of Clinical Innovative Medicine, Institute for Advancement of Clinical and Translational Science Kyoto University  Kyoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Graduate School of Medicine Kyoto University  Kyoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health Kyoto University  Kyoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Division of Clinical and Epidemiological Database, Department of Information Governance National Cerebral and Cardiovascular Center  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Department of Health Informatics, School of Public Health, Graduate School of Medicine Kyoto University  Kyoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhisa","family":"Bessho","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Graduate School of Medicine Kyoto University  Kyoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Yokode","sequence":"additional","affiliation":[{"name":"Department of Clinical Innovative Medicine, Institute for Advancement of Clinical and Translational Science Kyoto University  Kyoto Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,1,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080843"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2009.01.009"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.0707onj"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.99.132"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-2391(03)00720-1"},{"key":"e_1_2_8_7_1","unstructured":"U.S. Food and Drug Administration Memorandum.2003.http:\/\/www.fda.gov\/OHRMS\/DOCKETS\/ac\/05\/briefing\/2005\u20104095B2_03_03\u2010FDA\u2010TAB2.pdf(accessed 2013\/3\/5)"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(08)70305\u2010X"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.8670"},{"key":"e_1_2_8_10_1","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos MA","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.2465"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2006.11.003"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/jop.2006.2.1.7"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.14219\/jada.archive.2006.0355"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532\u20105415.2011.03371.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198\u2010009\u20101024\u20109"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e318245a160"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.308"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2012.08.115"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102012\u2010001622"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2008.02.012"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2008.09.031"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2010.05.003"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc1000"},{"key":"e_1_2_8_25_1","unstructured":"Pharmaceuticals and Medical Devices Agency Safety Information. September2010.http:\/\/www1.mhlw.go.jp\/kinkyu\/iyaku_j\/iyaku_j\/anzenseijyouhou\/272.pdf(accessed 1 February)"},{"key":"e_1_2_8_26_1","unstructured":"LambT.Did Merck Fail To Warn About Fosamax Side Effects?2006.http:\/\/www.drug\u2010injury.com\/druginjurycom\/2006\/04\/fosamax_drug_co.html(accessed 2013\/6\/30)"},{"key":"e_1_2_8_27_1","unstructured":"MERCK.Statement by Merck Regarding FOSAMAX\u00ae (alendronate sodium) and Rare Cases of Osteonecrosis of the Jaw 2010.http:\/\/www.mercknewsroom.com\/news\/statement\u2010merck\u2010regarding\u2010fosamax\u2010alendronate\u2010sodium\u2010and\u2010rare\u2010cases\u2010osteonecrosis\u2010jaw(accessed 2013\/6\/30)"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.100771"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.2165\/11539040\u2010000000000\u201000000"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2007.08.003"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.2165\/11599100\u2010000000000\u201000000"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn554"},{"key":"e_1_2_8_33_1","first-page":"b147","article-title":"Preventive strategies and clinical implications for bisphosphonate\u2010related osteonecrosis of the jaw: a review of 282 patients","volume":"77","author":"Bonacina R","year":"2011","journal-title":"J Can Dent Assoc"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.5794\/jjoms.53.392"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.5794\/jjoms.53.594"},{"key":"e_1_2_8_36_1","unstructured":"PMDA.Bisphosphonate\u2010Related Osteonecrosis of the Jaws.2009.http:\/\/www.mhlw.go.jp\/topics\/2006\/11\/dl\/tp1122\u20101l01.pdf(accessed 2013\/6\/3)"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.5794\/jjoms.55.553"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00774\u2010010\u20100162\u20107"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.3562","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.3562","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.3562","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.3562","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T13:04:03Z","timestamp":1696338243000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.3562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,8]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1002\/pds.3562"],"URL":"https:\/\/doi.org\/10.1002\/pds.3562","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,8]]}}}